(Circulation. 2003;108:2974.)
© 2003 American Heart Association, Inc.
Brief Rapid Communications |
From the Center for Clinical Pharmacology, Departments of Medicine (L.C.Z., E.K.J., D.G.G., R.K.D.) and Pharmacology (E.K.J.), University of Pittsburgh, Pittsburgh, Pa; the Department of Obstetrics and Gynecology, University Hospital, Zurich, Switzerland (F.B., R.K.D.); and the Laboratory of Human Neurogenetics, Rockefeller University (M.K.), and Department of Physiology and Cellular Biophysics, Center for Neurobiology and Behavior, Columbia University (J.A.G.), New York, NY.
Correspondence to Dr Raghvendra K. Dubey, Clinic for Endocrinology (D217, NORD-1), University Hospital Zurich, Frauenklinikstrasse 10, 8091 Zurich, Switzerland. E-mail raghvendra.dubey{at}usz.ch
Received September 29, 2002; revision received October 27, 2003; accepted October 30, 2003.
Background Studies using pharmacological agents suggest but do not prove that the antimitogenic effects of estradiol are caused by conversion of estradiol to hydroxyestradiols (mediated by CYP450s) followed by methylation of hydroxyestradiols to methoxyestradiols (mediated by catechol-O-methyltransferase, COMT).
Methods and Results To test this hypothesis more rigorously, we used aortic smooth muscle cells (SMCs) from mice lacking COMT (COMT-KO). Wild-type (WT) but not COMT-KO SMCs efficiently converted 2-hydroxyestradiol to 2-methoxyestradiol. Both WT and COMT-KO SMCs expressed estrogen receptors. Estradiol and 2-hydroxyestradiol concentration-dependently inhibited serum-induced DNA synthesis, cell numbers, and collagen synthesis in WT but not COMT-KO SMCs. 2-Methoxyestradiol inhibited DNA synthesis, cell numbers, and collagen synthesis in both WT and COMT-KO SMCs.
Conclusions These data provide strong evidence that the vascular antimitogenic effects of estradiol are estrogen receptorindependent and involve the sequential conversion of estradiol to hydroxyestradiols and then to methoxyestradiols.
Key Words: coronary disease hormones metabolism muscle, smooth receptors
This article has been cited by other articles:
![]() |
Y. Gui, X.-L. Zheng, J. Zheng, and M. P. Walsh Inhibition of rat aortic smooth muscle contraction by 2-methoxyestradiol Am J Physiol Heart Circ Physiol, November 1, 2008; 295(5): H1935 - H1942. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. M. Miller and S. P. Duckles Vascular Actions of Estrogens: Functional Implications Pharmacol. Rev., June 1, 2008; 60(2): 210 - 241. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Dubey, E. K. Jackson, D. G. Gillespie, L. C. Zacharia, D. Wunder, B. Imthurn, and M. Rosselli Medroxyprogesterone Abrogates the Inhibitory Effects of Estradiol on Vascular Smooth Muscle Cells by Preventing Estradiol Metabolism Hypertension, April 1, 2008; 51(4): 1197 - 1202. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Salih, S. A. Salama, M. Jamaluddin, A. A. Fadl, L. J. Blok, C. W. Burger, M. Nagamani, and A. Al-Hendy Progesterone-Mediated Regulation of Catechol-O-Methyl Transferase Expression in Endometrial Cancer Cells Reproductive Sciences, February 1, 2008; 15(2): 210 - 220. [Abstract] [PDF] |
||||
![]() |
R. K. Dubey, B. Imthurn, and E. K. Jackson 2-Methoxyestradiol: A Potential Treatment for Multiple Proliferative Disorders Endocrinology, September 1, 2007; 148(9): 4125 - 4127. [Full Text] [PDF] |
||||
![]() |
J. Bourghardt, G. Bergstrom, A. Krettek, S. Sjoberg, J. Boren, and A. Tivesten The Endogenous Estradiol Metabolite 2-Methoxyestradiol Reduces Atherosclerotic Lesion Formation in Female Apolipoprotein E-Deficient Mice Endocrinology, September 1, 2007; 148(9): 4128 - 4132. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Eichenlaub-Ritter, U. Winterscheidt, E. Vogt, Y. Shen, H.-R. Tinneberg, and R. Sorensen 2-Methoxyestradiol Induces Spindle Aberrations, Chromosome Congression Failure, and Nondisjunction in Mouse Oocytes Biol Reprod, May 1, 2007; 76(5): 784 - 793. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Salama, A. B. Nasr, R. K. Dubey, and A. Al-Hendy Estrogen Metabolite 2-Methoxyestradiol Induces Apoptosis and Inhibits Cell Proliferation and Collagen Production in Rat and Human Leiomyoma Cells: A Potential Medicinal Treatment for Uterine Fibroids Reproductive Sciences, December 1, 2006; 13(8): 542 - 550. [Abstract] [PDF] |
||||
![]() |
E. Seli, O. Guzeloglu-Kayisli, H. Cakmak, U. A. Kayisli, B. Selam, and A. Arici Estradiol Increases Apoptosis in Human Coronary Artery Endothelial Cells by Up-Regulating Fas and Fas Ligand Expression J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4995 - 5001. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Masi, L. C. Hawkley, J. D. Berry, and J. T. Cacioppo Estrogen Metabolites and Systolic Blood Pressure in a Population-Based Sample of Postmenopausal Women J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 1015 - 1020. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kappert, E. Caglayan, M. Huntgeburth, A. T. Baumer, J. Sparwel, M. Uebel, and S. Rosenkranz 17{beta}-Estradiol attenuates PDGF signaling in vascular smooth muscle cells at the postreceptor level Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H538 - H546. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Dubey, B. Imthurn, M. Barton, and E. K. Jackson Vascular consequences of menopause and hormone therapy: Importance of timing of treatment and type of estrogen Cardiovasc Res, May 1, 2005; 66(2): 295 - 306. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Kisselev, W.-H. Schunck, I. Roots, and D. Schwarz Association of CYP1A1 Polymorphisms with Differential Metabolic Activation of 17{beta}-Estradiol and Estrone Cancer Res., April 1, 2005; 65(7): 2972 - 2978. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Dubey, E. K. Jackson, D. G. Gillespie, M. Rosselli, F. Barchiesi, A. Krust, H. Keller, L. C. Zacharia, and B. Imthurn Cytochromes 1A1/1B1- and Catechol-O-Methyltransferase-Derived Metabolites Mediate Estradiol-Induced Antimitogenesis in Human Cardiac Fibroblast J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 247 - 255. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Dubey, B. Imthurn, L. C. Zacharia, and E. K. Jackson Hormone Replacement Therapy and Cardiovascular Disease: What Went Wrong and Where Do We Go From Here? Hypertension, December 1, 2004; 44(6): 789 - 795. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Dubey, E. K. Jackson, D. G. Gillespie, L. C. Zacharia, and B. Imthurn Catecholamines Block the Antimitogenic Effect of Estradiol on Human Coronary Artery Smooth Muscle Cells J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3922 - 3931. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C. Zacharia, C. A. Piche, R. M. Fielding, K. M. Holland, S. D. Allison, R. K. Dubey, and E. K. Jackson 2-Hydroxyestradiol Is a Prodrug of 2-Methoxyestradiol J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 1093 - 1097. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Barchiesi, E. K. Jackson, B. Imthurn, J. Fingerle, D. G. Gillespie, and R. K. Dubey Differential Regulation of Estrogen Receptor Subtypes {alpha} and {beta} in Human Aortic Smooth Muscle Cells by Oligonucleotides and Estradiol J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2373 - 2381. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |